Serkova V K, Zhebel' V N, Filenko L V, Savitskaia E A
Department of Therapy, Pirogov Vinnitsa Medical University, Ukraine.
Eksp Klin Farmakol. 1998 Mar-Apr;61(2):75-8.
The origin and development of ischemic heart disease (IHD) is attended with activation of lipid free-radical oxidation facilitating further advancement of the disease and with decrease of the organism's antioxidant protection. The antianginal drugs which are used in IHD treatment differ in their effect on the blood lipid composition and their peroxidation. beta-Adrenoblocking agents may cause proatherogenic disorders of the blood lipid graph, this increases the risk of IHD advancement. Long-acting nitro preparations are lipid-neutral. Calcium antagonists, mainly those of the nifedipin group, suppress LPO superactivity, possess a high antioxidant effect, and, probably, retard the advancement of coronary atherosclerosis and IHD.
缺血性心脏病（IHD）的发生与发展伴随着脂质自由基氧化的激活，这会促进疾病的进一步发展，同时机体的抗氧化保护作用会降低。用于治疗IHD的抗心绞痛药物对血脂成分及其过氧化的影响各不相同。β-肾上腺素能阻滞剂可能会导致血脂谱出现促动脉粥样硬化紊乱，这会增加IHD进展的风险。长效硝基制剂对血脂无影响。钙拮抗剂，主要是硝苯地平类，可抑制脂质过氧化超活性，具有较高的抗氧化作用，并且可能会延缓冠状动脉粥样硬化和IHD的进展。
